BR0211523A - 2-(3,5-bis-trifluorometil-fenil)-n-[6-,(1,1-dloxo-1lhi6 -tiomorfolin-4-il)-4(2-metil ou 4-flúor-2-metil substituìdo)fenil-piridin-3-il]-n-metilisobutiramida - Google Patents
2-(3,5-bis-trifluorometil-fenil)-n-[6-,(1,1-dloxo-1lhi6 -tiomorfolin-4-il)-4(2-metil ou 4-flúor-2-metil substituìdo)fenil-piridin-3-il]-n-metilisobutiramidaInfo
- Publication number
- BR0211523A BR0211523A BR0211523-9A BR0211523A BR0211523A BR 0211523 A BR0211523 A BR 0211523A BR 0211523 A BR0211523 A BR 0211523A BR 0211523 A BR0211523 A BR 0211523A
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- methyl
- disease
- pyridin
- bis
- Prior art date
Links
- -1 3,5-bis-trifluoromethyl-phenyl Chemical group 0.000 title abstract 4
- 206010047700 Vomiting Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000014181 Bronchial disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000020564 Eye injury Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000012545 Psychophysiologic disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000004081 narcotic agent Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
"2-(3,5-BIS-TRIFLUOROMETIL-FENIL)-N-16-(1,1-DIOXO-1LHI^ 6^-TIOMORFOLIN-4-IL)-4-(2-METIL OU 4-FLúOR-2-METIL SUBSTITUìDO)FENIL-PIRIDIN-3-IL]-N-METILISOBUTIRAMIDA". A invenção refere-se a compostos 2-(3,5-bis-trifluorometil-fenil)N-[6-(1,1 -dioxo-1<sym>^ 6^ -tiomorfolin-4-il)-4-o-tolil-piridin-3-il]-N-metil-isobutiramida e 2-(3,5-Bis-trifluorometil-fenil)-N-[6-(1,1-dioxo-1<sym>^ 6^-tiomorfolin-4-il)-4-(4-flúor2-metil-fenil)-piridin-3-il]-N-metil-isobutirami da, os quais podem ser usados para o tratamento de enxaqueca, artrite reumatóide, asma, hiperatividade brónquica, doença inflamatória dos intestinos ou para o tratamento de distúrbios incluindo mal de Parkinson, ansiedade, depressão, dor, dor de cabeça, mal de Alzheimer, esclerose múltipla, edema, rinite alérgica, mal de Crohn, ferimento ocular, doenças inflamatórias oculares, psicose, náusea por movimento, vómito induzido, êmese, incontinência urinária, distúrbios psicoimunológicos ou psicossomáticos, câncer, sintomas de retirada de drogas viciadoras a partir de narcóticos ou nicotina, dano cerebral traumático ou hiperplasia prostática benigna.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118412 | 2001-07-31 | ||
| PCT/EP2002/008311 WO2003011860A2 (en) | 2001-07-31 | 2002-07-26 | 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211523A true BR0211523A (pt) | 2004-09-14 |
Family
ID=8178193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211523-9A BR0211523A (pt) | 2001-07-31 | 2002-07-26 | 2-(3,5-bis-trifluorometil-fenil)-n-[6-,(1,1-dloxo-1lhi6 -tiomorfolin-4-il)-4(2-metil ou 4-flúor-2-metil substituìdo)fenil-piridin-3-il]-n-metilisobutiramida |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6849624B2 (pt) |
| EP (1) | EP1414525B1 (pt) |
| JP (1) | JP4700908B2 (pt) |
| KR (1) | KR100577101B1 (pt) |
| CN (1) | CN1289497C (pt) |
| AR (1) | AR034921A1 (pt) |
| AT (1) | ATE430600T1 (pt) |
| BR (1) | BR0211523A (pt) |
| CA (1) | CA2452502C (pt) |
| DE (1) | DE60232246D1 (pt) |
| EA (1) | EA006238B1 (pt) |
| EC (1) | ECSP044963A (pt) |
| ES (1) | ES2324209T3 (pt) |
| GT (1) | GT200200159A (pt) |
| HK (1) | HK1069136A1 (pt) |
| HR (1) | HRP20040039A2 (pt) |
| HU (1) | HUP0400398A3 (pt) |
| MA (1) | MA27055A1 (pt) |
| MX (1) | MXPA04000917A (pt) |
| MY (1) | MY128464A (pt) |
| NO (1) | NO20040404L (pt) |
| NZ (1) | NZ530579A (pt) |
| PA (1) | PA8551601A1 (pt) |
| PE (1) | PE20030276A1 (pt) |
| PL (1) | PL366986A1 (pt) |
| UA (1) | UA77685C2 (pt) |
| UY (1) | UY27403A1 (pt) |
| WO (1) | WO2003011860A2 (pt) |
| YU (1) | YU2704A (pt) |
| ZA (1) | ZA200400652B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE323531T1 (de) * | 2001-04-23 | 2006-05-15 | Hoffmann La Roche | Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| NO346973B1 (en) | 2002-12-20 | 2023-03-20 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
| RU2330022C2 (ru) * | 2003-01-31 | 2008-07-27 | Ф.Хоффманн-Ля Рош Аг | НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА |
| MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
| ES2329827T3 (es) * | 2005-02-22 | 2009-12-01 | F. Hoffmann-La Roche Ag | Antagonistas de nk1. |
| CN101128189A (zh) | 2005-02-25 | 2008-02-20 | 弗·哈夫曼-拉罗切有限公司 | 药物物质分散性改善的片剂 |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
| EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| RU2770050C2 (ru) | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
| EP3801514A1 (en) * | 2018-06-08 | 2021-04-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6435115A (en) * | 1987-07-31 | 1989-02-06 | Nippon Seiko Kk | Bearing device |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ATE278687T1 (de) | 1993-12-29 | 2004-10-15 | Merck Sharp & Dohme | Substituierte morpholinderivate und ihre verwendung als therapeutische mittel |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| ATE323531T1 (de) | 2001-04-23 | 2006-05-15 | Hoffmann La Roche | Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie |
-
2002
- 2002-07-17 US US10/196,795 patent/US6849624B2/en not_active Expired - Fee Related
- 2002-07-25 PE PE2002000667A patent/PE20030276A1/es not_active Application Discontinuation
- 2002-07-26 DE DE60232246T patent/DE60232246D1/de not_active Expired - Lifetime
- 2002-07-26 WO PCT/EP2002/008311 patent/WO2003011860A2/en active IP Right Grant
- 2002-07-26 CA CA2452502A patent/CA2452502C/en not_active Expired - Fee Related
- 2002-07-26 MX MXPA04000917A patent/MXPA04000917A/es active IP Right Grant
- 2002-07-26 PA PA20028551601A patent/PA8551601A1/es unknown
- 2002-07-26 EA EA200400109A patent/EA006238B1/ru not_active IP Right Cessation
- 2002-07-26 KR KR1020047001322A patent/KR100577101B1/ko not_active IP Right Cessation
- 2002-07-26 PL PL02366986A patent/PL366986A1/xx not_active Application Discontinuation
- 2002-07-26 YU YU2704A patent/YU2704A/sh unknown
- 2002-07-26 UA UA2004021462A patent/UA77685C2/uk unknown
- 2002-07-26 NZ NZ530579A patent/NZ530579A/en unknown
- 2002-07-26 ES ES02791471T patent/ES2324209T3/es not_active Expired - Lifetime
- 2002-07-26 BR BR0211523-9A patent/BR0211523A/pt not_active Application Discontinuation
- 2002-07-26 CN CNB028151100A patent/CN1289497C/zh not_active Expired - Fee Related
- 2002-07-26 AT AT02791471T patent/ATE430600T1/de active
- 2002-07-26 EP EP02791471A patent/EP1414525B1/en not_active Expired - Lifetime
- 2002-07-26 JP JP2003517052A patent/JP4700908B2/ja not_active Expired - Fee Related
- 2002-07-26 HU HU0400398A patent/HUP0400398A3/hu unknown
- 2002-07-29 AR ARP020102847A patent/AR034921A1/es not_active Application Discontinuation
- 2002-07-29 MY MYPI20022848A patent/MY128464A/en unknown
- 2002-07-30 UY UY27403A patent/UY27403A1/es not_active Application Discontinuation
- 2002-07-31 GT GT200200159A patent/GT200200159A/es unknown
-
2004
- 2004-01-15 HR HR20040039A patent/HRP20040039A2/hr not_active Application Discontinuation
- 2004-01-27 ZA ZA200400652A patent/ZA200400652B/xx unknown
- 2004-01-29 EC EC2004004963A patent/ECSP044963A/es unknown
- 2004-01-29 NO NO20040404A patent/NO20040404L/no unknown
- 2004-01-30 MA MA27507A patent/MA27055A1/fr unknown
-
2005
- 2005-02-28 HK HK05101662A patent/HK1069136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211523A (pt) | 2-(3,5-bis-trifluorometil-fenil)-n-[6-,(1,1-dloxo-1lhi6 -tiomorfolin-4-il)-4(2-metil ou 4-flúor-2-metil substituìdo)fenil-piridin-3-il]-n-metilisobutiramida | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| UY26813A1 (es) | Compuestos para tratar enfermedad de alzheimer | |
| WO1999065449A8 (en) | INHIBITORS OF TRANSCRIPTION FACTOR NF-λB | |
| DE60227658D1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| BR9408174A (pt) | Compostos isoxazolina como agentes antiinflamatórios | |
| MX2007012374A (es) | Metodos y composiciones para el tratamiento de condiciones relacionadas con cns. | |
| TW200609231A (en) | Mglur1 antagonists as therapeutic agents | |
| DE60110557D1 (de) | Aminoadamantan-derivate als therapeutische mittel | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| EA200500114A1 (ru) | Терапевтические агенты, используемые для лечения боли | |
| DK1593387T3 (da) | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser | |
| ATE455773T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| MX2008002366A (es) | Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos. | |
| ATE526981T1 (de) | Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen | |
| TW200740826A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| JP2005500354A5 (pt) | ||
| PL319868A1 (en) | Novel method of treating diseases | |
| CA2514037A1 (en) | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide | |
| EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
| WO2006089658A3 (en) | Nk1 antagonists | |
| TH63562A (th) | 2-(3,5-บิส-ไตรฟลูออโรเมทธิล-ฟีนิล)-n-[6-(1, 1-ไดออกโซ-1) 6-ไธโอมอร์โฟลีน-4-อิล)-4-(2-เมทธิล หรือ 4-ฟลูออโร-2-เมทธิลที่ถูกแทนที่)ฟีนิล-ไพริดีน-3-อิล]-n-เมทธิล-ไอโซบิวไทราไมด์ | |
| PT1282414E (pt) | Compostos derivados de felbamato para o tratamento da dor neuropatica | |
| HUP0401317A3 (en) | Novel use of subsituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders | |
| ECSP951549A (es) | Nuevo procedimiento de tratamiento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |